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Abstract
Regulatory T (Treg) cells play key roles in various 
immune responses. For example, Treg cells contribute 
to the complex pathogenesis of inflammatory bowel 
disease (IBD), which includes Crohn’s disease and 
ulcerative colitis during onset or development of that 
disease. Many animal models of IBD have been used 
to investigate factors such as pathogenic cytokines, 
pathogenic bacteria, and T-cell functions, including 
those of Treg cells. In addition, analyses of patients 
with IBD facilitate our understanding of the precise 
mechanism of IBD. This review article focuses on 
the role of Treg cells and outlines the pathogenesis 
and therapeutic strategies of IBD based on previous 
reports.
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Core tip: We review the types and functions of 
regulatory CD4+ T cells (Treg cells) and describe their 
roles in the pathologies of the inflammatory bowel 
diseases, i.e. , Crohn’s disease and ulcerative colitis. 
We have paid particular attention to the use of 
animal models and human studies to elucidate the 
mechanisms by which Treg cells influence these diseases 
and have provided an overview of the potential uses of 
these cells in therapeutic strategies.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a term that 
encompasses two major forms of chronic inflam­
matory intestinal disorders: Crohn’s disease (CD) 
and ulcerative colitis (UC)[1­3]. Both of these chronic 
inflammatory diseases feature a typical time of 
onset during young adulthood and a lifelong course 
characterized by periods of remission and relapse[4,5]. 
The pathogenesis of IBD is well known to be complex 
because of various immunological, environmental, host 
genetic, and bacterial factors, and the complicated 
regulatory mechanisms associated with mucosal 
immunity can also influence the onset or development 
of IBD[6­8]. Many reports of various animal models of 
IBD have revealed cellular or molecular mechanisms 
of IBD and the recent use of anticytokine agents, such 
as antitumor necrosis factor­α (TNF­α), interleukin 
(IL)­6R, or IL­13 antibodies, has achieved progress in 
healing mucosal damage associated with IBD[9,10].
Regulatory T (Treg) cells are known to plays a key 
role in the pathogenesis of IBD, as well as in other 
autoimmune disorders or allergies[11­14]. Considerable 
evidence supports the notion that an altered balance 
between Foxp3+CD4+ Treg cells and T effector cells in 
the intestinal microenvironment might contribute to 
the pathogenesis of IBD[12,15]. The ability to control 
inflammatory lesions with transferred Treg cells has 
been demonstrated in several IBD models[16,17]. On 
the other hand, patients with IBD have been found to 
harbor significantly reduced numbers of peripheral Treg 
cells or increased serum level of soluble IL­2Rα[18,19]. 
Therefore, it is possible that a novel therapy involving 
Treg cells might effectively treat IBD.
This review will focus on the functions of Treg cells 
in controlling peripheral immune tolerance within 
the context of mucosal immunity and will explain 
the molecular pathogenesis of IBD and possible 
therapeutic strategies involving Treg cells.
PATHOGENESIS OF IBD
The functions of mucosal immune system depend on 
the presence of intestinal flora[20]. In the intestinal 
epithelium, four cell types are found, including 
columnar cells, goblet cells, endocrine cells, and 
leukocytes to rest on a continuous basement lamina[21]. 
In addition, the immune cells in the lamina propria 
(LP), the leukocytes also involve various immune cells, 
such as the unique immune cell types that exist in 
gut­ or mucosa­associated lymphoid tissues such as 
Peyer’s patches, mesenteric lymph nodes, and isolated 
lymphoid follicles. Balanced mucosal immunity in the 
gut is important for both immune homeostasis and 
defense[22­24]. Intestinal immunity is maintained by 
the proportions of immune cells such as dendritic cells 
(DCs), macrophages, effector CD4+ or CD8+ T cells, 
and Treg cells.
Previously reported genome­wide association 
studies have identified more than 100 distinct loci 
that confer risk or protection from IBD development 
although a substantial proportion of these loci are 
common to both diseases[6]. Many IBD­associated 
pathways are known to exert heterogeneous effects 
upon activation in different cell types, and the 
combination of these cellular outcomes might affect 
disease manifestation[8,25]. IBD­associated loci can be 
broadly categorized into several critical pathways such 
as the innate immune response, intestinal barrier, 
microbial defense, reactive oxygen, and antimicrobial 
activity[26]. For example, in humans, nucleotide­binding 
oligomerization domain­containing protein 2 (NOD2), 
which is encoded by the NOD2 gene on chromosome 
16 plays an important role in the intestinal immune 
system where it recognizes bacterial peptides and 
stimulates immune reactions[27]. Mutations in NOD2 
gene have been associated with CD[27]. Furthermore, 
NOD2­/­ mice are susceptible to and demonstrate 
excessive intestinal inflammation when compared 
with control mice[28]. Treatment with NOD2 ligands, 
including peptide or muramyl dipeptide has been 
shown to ameliorate 2,4,6­trinitrobenzenesulfonic acid 
(TNBS)­ or dextran sulfate sodium (DSS)­driven colitis 
in normal mice[29,30]. Treatment with Lactobacillus 
peptidoglycan was shown to increase the number of 
CD103+DCs and Foxp3+ Treg cell in mesenteric lymph 
nodes and IL­10 expression in the colonic mucosa 
in a TNBS­driven model of colitis, suggesting that 
NOD2 activity in the intestinal mucosa potentiates a 
tolerogenic environment[30].
Homing or migration­associated receptors such 
as CD62L, C­C chemokine receptor (CCR)7, αEb7 
integrin, α4b7 integrin, CCR4, CCR5, and CCR9 
also contribute to the pathogenesis of IBD[31­37]. The 
expression of these receptors on Treg cells plays a 
key role in the intestinal immunological homeostasis 
and defective expression of these receptors has 
been shown to induce IBD as a result of the deficient 
migration of Treg cells into the intestine. For example, a 
loss of CCR7 was found to block Treg cell function in an 
experimental model of colitis[32].
ANIMAL MODELS OF IBD AND Treg CELLS
Many animal models of IBD have been developed 
based on the various aspects in the pathogenesis or 
mechanisms of IBD[16,38]. Mice have been widely used 
to examine the contribution of bacteria and specific 
bacterial factors to the pathogenesis of IBD[9]. Studies 
conducted in germ­free, specific pathogen­free, and 
gnotobiotic mice have suggested that defined or 
specific microbial flora plays a fundamental role in 
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the initiation and development of IBD[39­41]. Additional 
experimental colitis mouse models have been induced 
using chemical drugs such as DSS, TNBS, oxazolone, 
or acetic acid[9,42­46]. In addition, adoptive transfer 
models in which a T­cell deficient mouse strain is 
reconstituted with Treg cell­depleted naïve T cells from 
a congenic donor mouse have been widely used[16,38,47]. 
Additional genetic models, including gene knockout, 
transgenic, or mutant animals, have been utilized to 
understand the genetic and molecular pathogenesis 
of IBD[9,16,38]. As spontaneous models of IBD, several 
animal models mice and rats are known to understand 
the pathogenesis of IBD or investigate new therapeutic 
strategy for IBD[9,38].
Bacteria-infected models
Studies conducted in mouse models of IBD have 
indicated that the Treg cell compartment is particularly 
sensitive to microbiotal changes[48]. Treg cells from 
germ­free mice are generally less suppressive and 
express lower level of Foxp3 than do Treg cells from 
normal mice[49­51]. The colons of germ­free mice harbor 
reduced number of Treg cells, although this population 
was shown to increase in response to a decrease in 
bacterial load following vancomycin treatment[52,53]. 
Citrobactor rodentium-infected mouse models have 
been the preferred infection models in acute intestinal 
inflammation[54]. Helicobactor­infected mice have 
been also used to be a bacterial infection model in 
combination with the other model[47]. In addition, toll­
like receptor 9 (TLR9)-deficient mice harbor increased 
numbers of Treg cells in the small intestine, suggesting 
that inflammatory signals from bacterial DNA play a 
role in inhibiting induced Treg cell differentiation or Treg 
cell proliferation[12,55].
Gene-manipulated models
IL-2­/­, IL-2R­/­, and IL-10­/­ mice are known IBD 
models in which reduced Treg cell number or dys­
function of Treg cells are observed[41,19,56­60]. In addition, 
innate or mucosal immunity­related gene­deficient 
mice, such as NOD2­/­, myeloid differentiation primary 
response 88 (MYD88)­/­, nuclear factor­kB (NF-kB)­/­, 
cytokine­deficiency induced colitis susceptibility 1 
(CDCS1)­/­, multidrug resistance gene 1a (MDR1a)­/­, 
and TLR5­/­ mice, also reveal inflammatory lesions in 
the colon[27,61­70]. T­cell receptor (TCR)­/­ mice are also 
known to be one of IBD models[60]. Overexpression 
of TNF-α  and signal transducer and activator of 
transcription4 (STAT4) gene in mice results in the 
development of IBD­like lesions[16,71]. Moreover, there 
are various gene­manipulated models, in which 
epithelial barrier­ and immune regulation­associated 
genes are manipulated by knockdown, knockin, 
conditional knockout, or transgenic mice (Table 
1)[9,16,38,39,72­82]. Among them, a reduction of Treg cell 
number or impaired Treg cell function is observed in 
several models (Table 1)[19,59,60,68,72,77,78].
Spontaneous models
As one of spontaneous IBD models based on the 
pathogenic factor by Treg cells, senescence­accelerated 
mouse protein (SAMP)1/YitFc (SAMP) mice are well 
known[83]. A functional abnormality in Treg cells in 
SAMP mice is observed[83]. C3H/HeJBir mice with 
high susceptibility to bacteria have been also used to 
be a model of IBD[84]. In addition, a monkey model, 
cotton­top tamarin, infected with Campylobactor 
Jejuni is known to be a spontaneous model of 
IBD[85]. Moreover, long­evans cinnamon (LEC) rat is a 
spontaneous IBD model based on Treg cell­associated 
pathogenicity[86]. The LEC rat was first described as a 
naturally occurring mutant with a defect in thymocyte 
development: specifically, T­cell differentiation is 
arrested at the transition from CD4+CD8+ double 
positive to CD4+CD8­ single positive (SP), but not to 
CD4­CD8+ SP, thymocytes[87]. Accordingly, in LEC rats, 
peripheral CD4+ T cells did not function as Th cells in 
terms of antibody production against T cell­dependent 
antigens, as well as in IL­2 production[87]. In addition, 
significantly reduced numbers of thymic and peripheral 
Foxp3+Treg cell and a defect in the suppressive 
activity of Treg cells were observed in these rats[86]. 
Interestingly, the proportion of Treg cells in the LP is 
significantly decreased in LEC rats when compared 
with control rats[86]. These findings suggest that the 
dysfunction in the Treg cell­controlled regulatory system 
may play a crucial role in the development of IBD.
REGULATORY T CELL
Differentiation of Treg cells
Forkhead box P3 (Foxp3)­expressing Treg cells are 
a suppressive subset of CD4+ T cells that control 
autoimmunity, allergy, infection, and tumors[11,88]. 
Natural Treg (nTreg) cells arise as a discrete and largely 
stable lineage in the thymus[89,90]. The nTreg subset 
exhibits a TCR repertoire that is distinct from those of 
Foxp3­conventional T cells and induced (iTreg) cells[91­94].
nTreg cells require IL­2 for the development and 
maintenance and were initially identified by their 
elevated expression of the high­affinity IL­2 receptor 
(CD25)[11]. Mice that lack the ability to conduct IL­
2­mediated signaling following the injection of 
anti­IL­2 mAb or as a result of IL-2 or IL-2R gene 
knockout exhibit defects in the number and function 
of nTreg cells[95­98]. The most important finding in mice 
with deficient IL­2 signaling is the development of 
spontaneous autoimmune lesions, including IBD[96­98].
nTreg cells share phenotypic features with naïve 
and memory conventional T cells[89]. Most Treg cells in 
circulation and the lymphoid organs express CCR7 
and the adhesion receptor CD62L, which direct their 
recirculation through lymphoid tissues; effector 
or activated Treg cells comprise a minor fraction 
of these[88,99]. Similar to activated conventional T 
cells, this Treg cell population exhibits phenotypes 
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Table 1  Animal models of inflammatory bowel disease
such as CD62LloCCR7loCD44hi killer cell lectin­like 
receptor subfamily G member 1 (KLRG1)+CD103+ 
or CD45RAloCD25hi is thought to have encountered 
antigens[33,100­102]. These cells exhibit enhanced 
migration through nonlymphoid tissues.
Tissue­resident Treg cells can be found in non­
lymphoid tissues, even under noninflammatory 
conditions[89,103]. Various tissues such as the skin, 
lungs, liver, salivary gland, lacrimal gland, intestinal 
mucosa, adipose tissue, and placenta are known 
to harbor substantial numbers of Treg cells in both 
humans and mice[14,104]. For example, CCR7+Foxp3+ 
Treg cells were found to reside in the salivary glands 
of healthy humans and mice whereas the number 
of CCR7+Foxp3+ Treg cells was extremely decreased 
in the tissues from patients and model mice with 
Sjögren’s syndrome, an autoimmune disease that 
affects the exocrine glands such as the salivary and 
lacrimal glands[104,105].
Peripheral Treg cells
iTreg cells are generated from peripheral naïve 
conventional CD4+ T cells during the course of an 
immune response[12]. In healthy mice, most peripheral 
Treg cells in the spleen and lymph nodes are thymus­
derived nTreg cells. By contrast, the iTreg population 
resides in the intestinal LP and gut­associated 
lymphoid tissue (GALT)[48,106]. iTreg cell generation 
involves naïve T­cell activation in the presence of 
transforming growth factor­b (TGF­b): in this setting, 
antigen exposure induces iTreg cell differentiation[107]. 
iTreg cells are particularly prevalent at mucosal surfaces 
where tolerance is induced against various antigens 
within the colonizing microbiota[52,108]. In addition, 
ingested food contains a plethora of antigens: in 
particular, food antigen feeding experiments identified 
a TGF­b1­producing CD4+ T cell population in the LP 
and GALT[109]. Immune responses to these dietary 
molecules can be actively suppressed by inducing oral 
tolerance[110]. Experiments with germ­free mice have 
suggested that bacterial commensals are essential 
for the development of normal numbers of colonic 
Treg cells[109]. In the human microbiota, 17 clostridial 
strains that induce Treg cell gut­homing and expansion 
by producing large amounts of short­chain fatty acids 
(SCFAs), which are bacterial breakdown products 
of plant­derived fibers were identified[111,112]. In 
particular, the SCFAs propionate, butyrate, and acetate 
can restore clonal Treg cell numbers in germ­free or 
antibiotic­treated mice[112].
Although the gastrointestinal tract harbors the 
largest reservoir of tissue­resident Treg cells in the 
Group Model Association Ref.
Chemical drug-induced model DSS TNF-α, IL-17, reduced Treg cells [43]
TNBS IL-12, IL-17, reduced Treg cells [44]
Oxazolone IL-4 [45]
Acetic acid (rat) Myeloperoxidase [46]
Adoptive transfer model Naïve T cell→Rag-/-/SCID Recovery by Treg cell transfer [16]
Bacteria-infected model C. rodentium Acute infection, IL-17 [54]
Helicobacter, etc. Combined with the other models [47]
Spontaneous model SAMP/Yit/Fc Dysfunction of Treg cell [83]
C3H/HeJBir Increased susceptibility to bacteria [84]
Cotton-top Tamarin (monkey) C.Jejuni infection [85]
LEC (rat) Reduced Treg cells [86]
Gene-manipulated model IL-2-/- Reduced Treg cells [59]
IL-2R-/- Reduced Treg cells [19]
IL-10-/- Reduced Treg cells [60]
NOD2-/- Impaired innate immunity [61]
Myd88-/- Impaired TLR signal [65]
NF-kB-/- Impaired pro-inflammatory signal [62]
Cdcs1-/- Impaired pro-inflammatory signal [67]
Mdr1a-/- Reduced iTreg cell differentiation [68]
TCR-/- Defective adaptive immunity [60]
TGFb -/- Reduced Treg cell [72]
JAK3-/- Balance of Th1 and Th2 [73]
Muc2-/- ER stress [74]
A20-/- Impaired Myd88 signal [75]
TCR-/-SOCS1-/- Increased IFN-γ and IL-4 [76]
CD4/TGFb -/- Impaired Treg cell function [77]
CD4/PDK1-/- Reduced Treg cell [78]
CD4/Blimp1-/- Increased IL-17 [79]
TNF∆ARETG Increased CD8 function [71]
STAT4TG Increased TNF-α [80]
T/CD40LTG Thymic dysfunction [81]
B/CD40LTG Increased IFN-γ [82]
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body, recent studies have demonstrated that Treg 
cells are also highly enriched in the visceral adipose 
tissue (VAT)[113]. Interestingly, more than 50% Treg 
cells of CD4+ T cells in the VAT of 20­week­old mice 
are found[113]. Differences in the expressions of IL­10, 
CCR1, CCR2, CCR4, GATA binding protein 3 (GATA3), 
and peroxisome proliferator­activated receptor γ 
(PPARγ) have been observed between VAT Treg cells and 
effector Treg cells in lymphoid tissues[113,114]. Moreover, 
mice with a Treg cell-specific PPARγ deletion that were 
fed a high­fat diet exhibited impaired restoration of 
insulin sensitivity and glucose tolerance following 
pioglitazone treatment[113,114]. These findings suggest 
that VAT Treg cells might be critical mediators of the 
effects of treatment for lipid metabolism disorders.
REGULATOY T CELL IN IBD
Phenotypes of Treg cells in IBD
The phenotype and function of Treg cells in the inflamed 
mucosa or periphery of patients with IBD or animal 
models have been described as considerably different 
from those in peripheral lymphoid organs of healthy 
controls[12,115] (Figure 1). For example, patients with 
IBD exhibit reduced numbers of peripheral Treg cells 
and increased numbers peripheral Th17 cells[116]. By 
contrast, the mRNA expression levels of Foxp3 are 
elevated in the mucosa of patients with IBD along with 
elevated levels of IL­17A, IL­1b, and IL­6 mRNA[116]. 
In IBD models, dysfunctional suppressive Treg cell 
function plays a crucial role in the development of IBD 
lesions via the upregulation of T­cell specific T­box 
transcription factor (T­bet), STAT­1, and nuclear factor­
kB (NF­kB)­mediated peripheral Treg cell activation[86]. 
Intestinal immune system activation in response to 
bacterial antigens and pathologic cytokine production 
by intestinal T cells is induced through various 
transcription factors or signal molecules, including 
T­bet, GATA­3, and STATs and plays a critical role in 
the development of IBD[72,117­119]. CD is associated with 
the production of Th1 cytokines such as IFN­γ and 
TNF­α and in an IBD model naïve T cells transferred 
into T cell­deficient mice can be controlled by a 
coinjection of Treg cells which suppress Th1 effector cell 
Effector T cell↑
IBD lesion
IBD (periphery) 
Peripheral Treg cell↓ Th17 cell↑
Treg cell↓
IFN-γ IL-17
UC: Th1 < Th2
CD: Th1 > Th2
IL-17A, IL-1b, IL-15, IL-16, IFN-γ
TNF-α, IL-22, TGF-b, IL-18, IL-10
Relative chemokine receptors and adhesion molecules
CCR4, CCR5, CCR7, CCR9, CD62L, 
αEb7 integrin, α4b7 integrin
T-bet, STATs, GATA3, NF-kB, NOD2
Related cytokines
Relative transcription factor
Figure 1  Molecular contribution to the pathogenesis of inflammatory bowel disease. In the lesions of inflammatory bowel disease (IBD), a various immune cells 
and epithelial cells contribute to the onset or development of the disease. Imbalance between cytokines or abnormal expression of chemokine receptors and adhesion 
molecules through several transcription factors in immune cells including effector T cell influences the pathogenesis of IBD. Decreased number of Treg cells and 
abnormal differentiation of Treg cells into effector-like phenotype are observed in the IBD lesions.
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functions such as IFN­γ production[120,121]. Moreover, 
UC development in humans is associated with Th2 
cytokines such as IL­5[122].
Recent studies have demonstrated that Foxp3+ 
Treg cells express retinoic acid receptor­related orphan 
receptor gamma t and are thus able to differentiate 
into Th17 cells, a process that is associated with a 
decreased suppressive Treg cell function in patients 
with IBD. Treg cells were found to suppress colonic 
inflammation by downregulating Th17 responsiveness 
via TGF­b in an adoptive transfer mouse model of 
colitis[123,124]. Additionally, CCR7 was shown to regulate 
the intestinal Th1/Th17/Treg cell balance during CD­
like murine ileitis[125]. Furthermore, IFN­γ+IL­17+ 
coproducing CD4+ T cells which express high levels 
of T­bet, CD26, and IL­22 resemble the pathogenic 
Th17 cells that contribute to intestinal inflammation 
in IBD[126]. Epithelial­derived IL­18 also regulates 
both colonic Th17 cell differentiation and Treg cell 
function in the context of IBD­associated intestinal 
inflammation[124].
A recent study described Clostridium bacteria 
as potent inducers of Foxp3+ Treg cells in the colonic 
mucosa[111]. Additionally, CD4+CD8+αα colonic Treg 
cells were reported to produce IL­10 in response to 
Faecalibacterium prausnitzii and the frequencies of 
CD4+CD8+αα lymphocytes in the LP lymphocytes 
and peripheral blood were found to be significantly 
lower in patients with IBD than in healthy controls[127]. 
These findings suggest that colonic bacteria­induced 
CD4+CD8+αα Treg cells may control or prevent IBD.
Therapeutic Treg cell-based strategies for IBD
New and effective therapies involving anti­TNF 
antibodies have yielded remarkable progress in the field 
of IBD therapy[10]. In addition, clinical trial applications 
are underway for target molecules such as IL­6/IL­6R, 
IL­12/23, IL­17A/F, IL­13, interferon­gamma­inducible 
protein 10 (IP10), CCR9, Janus kinase 3 (JAK3), similar 
to mothers against decapentaplegic (Smad)7/TGF, 
α4b7/b7, and mucosal vascular addressin cell adhesion 
molecule (MAdCAM)[4,5]. Target molecules such as 
IL­17A/F, IL­13, IP10, JAK3, α4b7/b7, or MAdCAM 
also represent promising therapeutic strategies for 
UC[4,5,15,22,24].
The Foxp3+Treg cell frequency was found to be 
significantly lower in active patients with IBD than in 
healthy controls[18,116]. On day 14 after an initial dose of 
anti­TNFα infusion therapy, patients with IBD exhibited 
a significant increase in the frequency of circulating Treg 
cells along with two­ to three­fold increase in Foxp3 
expression, which paralleled a reduction of IBD[128]. 
Furthermore, another report demonstrated that 
anti­TNFα mAb [infliximab (IFX)] therapy yielded a 
significant and sustained relative increase in peripheral 
blood Treg cells; a change in C­reactive protein levels 
and durable clinical response was associated with this 
sustained increase in circulating Foxp3+Treg cells[129]. IFX 
therapy was also shown to downregulate the mucosal 
expression of Foxp3 mRNA and protein in patients with 
UC and CD[129].
In patients with active IBD, anti­TNF­α treatment 
rapidly enhances the frequency of functional Foxp3+Treg 
cells in the blood and potentiates their suppressive 
function[128]. In addition, in these patients increased 
apoptosis of local Foxp3+Treg cells is observed in the 
inflamed mucosa when compared with noninflamed 
control colon tissues, along with a reduced frequency 
and increased apoptosis of peripheral blood Treg cells 
and elevated caspase activity in the serum[130]. During 
anti­TNF­α antibody treatment, a decrease in the 
apoptosis of Treg cells was found to correlate closely 
with an increase in peripheral Treg cell numbers and a 
decrease of caspase and disease activity[130].
CD4+CD25+CD127loCD45RA+ Treg cells appear to 
be a promising population from which to expand 
Treg cells for autologous Treg cell transfer therapy in 
patients with CD[131]. Expanded CD45RA+ Treg cells 
carry an epigenetically stable FOXP3 locus and do not 
convert to a Th17 phenotype in in vitro culture and 
CD45RA+ Treg cells from patients with CD were found 
to home to the human small intestine in a C.B­17 
severe combined immune deficiency xenotransplant 
model[131]. There remains an unmet need for the 
development of novel therapies for IBD, as current 
drug therapies frequently fail to maintain long­term 
remission and may be complicated by significant side 
effects. Although cellular therapies are emerging as a 
potentially attractive many hindrances to successful 
clinical therapy remain in terms of sufficient cell 
numbers, cell maintenance, and cell sources.
CONCLUSION
Although the precise molecular pathogenesis of IBD 
remains unclear, recent therapeutic strategies involving 
antibodies against pathogenic cytokines or chemokines 
have provided treatment opportunities for many more 
patients suffering from IBD. Additionally, Treg cells may 
provide a more effective therapy for IBD; therefore 
the unknown mechanisms with respect to Treg cell 
differentiation, function, and maintenance should be 
clarified.
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